Myocardial tissue analysis reveals a concerning age-related decline in cardiac CoQ10 levels: a 30 percent reduction occurs naturally between ages 20 and 40, with further deterioration continuing into later decades. This depletion has direct consequences for cellular energy production, as CoQ10 is the only mobile electron carrier in the inner mitochondrial membrane.
Statin therapy accelerates this decline by blocking the mevalonate pathway that produces CoQ10. The combination of natural age-related depletion and statin-induced reduction creates a compounded effect on cardiac energy metabolism, particularly in older patients with cardiovascular disease requiring cholesterol management.
These findings underscore the importance of monitoring CoQ10 status in aging populations, especially those on long-term statin regimens. Read the full article on GMJ Newsroom.
Was this article helpful?
